Renaissance Technologies LLC Acquires 365,700 Shares of Cellebrite DI Ltd. $CLBT

Renaissance Technologies LLC increased its stake in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 14.7% during the first quarter, HoldingsChannel reports. The fund owned 2,860,639 shares of the company’s stock after buying an additional 365,700 shares during the period. Renaissance Technologies LLC’s holdings in Cellebrite DI were worth $39,420,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in CLBT. Towarzystwo Funduszy Inwestycyjnych PZU SA raised its holdings in shares of Cellebrite DI by 81.0% in the fourth quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 1,900 shares of the company’s stock valued at $34,000 after purchasing an additional 850 shares during the last quarter. Advisory Services Network LLC bought a new position in Cellebrite DI in the third quarter valued at $40,000. CWM LLC increased its stake in Cellebrite DI by 57.0% in the 4th quarter. CWM LLC now owns 2,449 shares of the company’s stock valued at $44,000 after buying an additional 889 shares during the last quarter. First Horizon Corp increased its stake in Cellebrite DI by 421.8% in the 4th quarter. First Horizon Corp now owns 2,891 shares of the company’s stock valued at $52,000 after buying an additional 2,337 shares during the last quarter. Finally, Vestcor Inc bought a new stake in Cellebrite DI during the 3rd quarter worth about $70,000. 45.88% of the stock is owned by institutional investors.

Cellebrite DI Trading Up 3.0%

NASDAQ CLBT opened at $14.64 on Tuesday. The firm has a market capitalization of $3.65 billion, a P/E ratio of 52.29, a price-to-earnings-growth ratio of 1.76 and a beta of 1.17. The firm’s fifty day moving average price is $14.21 and its two-hundred day moving average price is $14.26. Cellebrite DI Ltd. has a 1 year low of $11.02 and a 1 year high of $19.98.

Insider Activity

In related news, CRO Marcus Jewell sold 12,658 shares of Cellebrite DI stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $12.77, for a total transaction of $161,642.66. Following the completion of the transaction, the executive owned 440,101 shares in the company, valued at approximately $5,620,089.77. This trade represents a 2.80% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Thomas E. Hogan sold 103,188 shares of the business’s stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $15.76, for a total value of $1,626,242.88. Following the transaction, the chief executive officer directly owned 590,777 shares in the company, valued at approximately $9,310,645.52. This trade represents a 14.87% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 158,191 shares of company stock valued at $2,479,438. 5.70% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of research firms have recently commented on CLBT. Weiss Ratings upgraded shares of Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, May 18th. DA Davidson started coverage on Cellebrite DI in a research report on Wednesday, May 27th. They issued a “buy” rating and a $20.00 target price on the stock. Finally, Needham & Company LLC dropped their target price on Cellebrite DI from $18.00 to $15.00 and set a “buy” rating on the stock in a report on Friday, May 15th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, Cellebrite DI has a consensus rating of “Moderate Buy” and a consensus target price of $21.40.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.